G1 Therapeutics buy Needham & Company LLC
Start price
12.04.24
/
50%
€4.30
Target price
12.04.25
€11.28
Performance (%)
-19.40%
Price
29.04.24
€3.47
Summary
This prediction is currently active. The price of G1 Therapeutics has decreased since the start of the prediction. Compared to the start price this results in a performance of -19.40%. This prediction currently runs until 12.04.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w |
|---|---|
| G1 Therapeutics | -9.834% |
| iShares Core DAX® | 0.961% |
| iShares Nasdaq 100 | 2.626% |
| iShares Nikkei 225® | 0.217% |
| iShares S&P 500 | 1.540% |
Comments by Needham___Company_LL for this prediction
In the thread G1 Therapeutics diskutieren
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Ratings data for GTHX provided by MarketBeat